Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
367 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.
Crawford TO, Servais L, Mercuri E, et al. · Lancet Neurol · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS, Mercuri E, Darras BT, et al. · N Engl J Med · 2017Clinical Trial, Phase III, Multicenter Study
- Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy.
Mendell JR, Al-Zaidy S, Shell R, et al. · N Engl J Med · 2017Clinical Trial, Phase I, Clinical Trial, Phase II
- Risdiplam in Presymptomatic Spinal Muscular Atrophy.
Finkel RS, Servais L, Vlodavets D, et al. · N Engl J Med · 2025Clinical Trial, Phase II, Multicenter Study
- Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. · Lancet Neurol · 2024Randomized Controlled Trial, Multicenter Study
- Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G, Darras BT, Day JW, et al. · N Engl J Med · 2021Clinical Trial, Phase II, Clinical Trial, Phase III
- An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies.
Giess D, Erdos J, Wild C · Eur J Paediatr Neurol · 2024Systematic Review
- Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.
Proud CM, V© DC, Wilmshurst JM, et al. · Nat Med · 2026Clinical Trial, Phase III, Randomized Controlled Trial
- Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review.
Aragon-Gawinska K, Mouraux C, Dangouloff T, et al. · Genes (Basel) · 2023Systematic Review
- Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis.
Chongmelaxme B, Yodsurang V, Vichayachaipat P, et al. · Gene Ther · 2025Meta-Analysis, Systematic Review
- Systematic Review and Meta-analysis of Long-Term Nusinersen Effectiveness in Adolescents and Adults with Spinal Muscular Atrophy.
Hagenacker T, Paradis AD, Lawson-Michod KA, et al. · Adv Ther · 2025Systematic Review, Meta-Analysis
- Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
Day JW, Finkel RS, Chiriboga CA, et al. · Lancet Neurol · 2021Clinical Trial, Phase III, Multicenter Study
- Combination therapies in spinal muscular atrophy: a systematic review.
Bemanalizadeh M, Heidary L, Dakkali MS, et al. · Eur J Pediatr · 2025Systematic Review
- High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.
Finkel RS, Crawford TO, Mercuri E, et al. · Nat Med · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Systematic Literature Review of the Natural History of Spinal Muscular Atrophy: Motor Function, Scoliosis, and Contractures.
Aponte Ribero V, Martí Y, Batson S, et al. · Neurology · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E, Darras BT, Chiriboga CA, et al. · N Engl J Med · 2018Clinical Trial, Phase III, Comparative Study
- Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy: A Nonrandomized Controlled Trial.
Schwartz O, Vill K, Pfaffenlehner M, et al. · JAMA Pediatr · 2024Controlled Clinical Trial, Multicenter Study
- Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy.
Proud CM, Finkel RS, Parsons JA, et al. · J Clin Invest · 2025Clinical Trial, Phase IV, Multicenter Study
- Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Crawford TO, Darras BT, Day JW, et al. · Neurology · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS, Chiriboga CA, Vajsar J, et al. · Lancet · 2016Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- A Systematic Literature Review of the Natural History of Respiratory, Swallowing, Feeding, and Speech Functions in Spinal Muscular Atrophy (SMA).
Martí Y, Aponte Ribero V, Batson S, et al. · J Neuromuscul Dis · 2024Systematic Review
- Newborn screening of neuromuscular diseases.
Dangouloff T, Boemer F, Servais L · Neuromuscul Disord · 2021Systematic Review
- Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
Guglieri M, Bushby K, McDermott MP, et al. · JAMA · 2022Comparative Study, Randomized Controlled Trial
- The effect of thoracolumbosacral orthosis on scoliosis progression and chest deformity in children with type 1 spinal muscular atrophy: A randomized controlled trial.
Dansuk E, Van Den Berg ANT, Ata G, et al. · PLoS One · 2025Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.
Thomsen G, Burghes AHM, Hsieh C, et al. · Nat Med · 2021Clinical Trial, Phase I, Multicenter Study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.